Literature DB >> 20421274

Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.

Hussam Ghoti, Eitan Fibach, Drorit Merkel, Galit Perez-Avraham, Sigal Grisariu, Eliezer A Rachmilewitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20421274      PMCID： PMC2913096          DOI： 10.3324/haematol.2010.024992

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

Review 1.  Management of anemia associated with myelodysplastic syndrome.

Authors:  E Hellström-Lindberg
Journal:  Semin Hematol       Date:  2005-04       Impact factor: 3.851

2.  Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants.

Authors:  Johnny Amer; Hussam Ghoti; Eliezer Rachmilewitz; Ariel Koren; Carina Levin; Eitan Fibach
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

Review 3.  Intracellular labile iron.

Authors:  William Breuer; Maya Shvartsman; Z Ioav Cabantchik
Journal:  Int J Biochem Cell Biol       Date:  2007-03-19       Impact factor: 5.085

4.  Iron: The fifth horseman of the apocalypse?

Authors:  Thomas G DeLoughery
Journal:  Am J Hematol       Date:  2009-05       Impact factor: 10.047

Review 5.  Pathophysiology of iron overload.

Authors:  C Hershko; G Link; I Cabantchik
Journal:  Ann N Y Acad Sci       Date:  1998-06-30       Impact factor: 5.691

Review 6.  LPI-labile plasma iron in iron overload.

Authors:  Z Ioav Cabantchik; William Breuer; G Zanninelli; P Cianciulli
Journal:  Best Pract Res Clin Haematol       Date:  2005-06       Impact factor: 3.020

7.  Redox state of glutathione in human plasma.

Authors:  D P Jones; J L Carlson; V C Mody; J Cai; M J Lynn; P Sternberg
Journal:  Free Radic Biol Med       Date:  2000-02-15       Impact factor: 7.376

Review 8.  Myelodysplastic syndromes.

Authors:  Peter L Greenberg; Neal S Young; Norbert Gattermann
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2002

9.  Myelodysplasia paranoia: iron as the new radon.

Authors:  David P Steensma
Journal:  Leuk Res       Date:  2008-11-25       Impact factor: 3.156

10.  Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome.

Authors:  Hussam Ghoti; Johnny Amer; Asher Winder; Eliezer Rachmilewitz; Eitan Fibach
Journal:  Eur J Haematol       Date:  2007-11-01       Impact factor: 2.997
View more
  25 in total

Review 1.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

2.  Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

3.  Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT.

Authors:  G Visani; B Guiducci; C Giardini; F Loscocco; T Ricciardi; A Isidori
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

Review 4.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

5.  Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.

Authors:  Minoru Kojima; Shinichiro Machida; Ai Sato; Mitsuki Miyamoto; Makiko Moriuchi; Yoshiaki Ohbayashi; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2013-10-26       Impact factor: 2.490

6.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

7.  Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients.

Authors:  Ana Cristina Gonçalves; Emília Cortesão; Barbara Oliveiros; Vera Alves; Ana Isabel Espadana; Luís Rito; Emília Magalhães; Sónia Pereira; Amélia Pereira; José Manuel Nascimento Costa; Luisa Mota-Vieira; Ana Bela Sarmento-Ribeiro
Journal:  Clin Exp Med       Date:  2015-05-17       Impact factor: 3.984

8.  Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.

Authors:  John C Wood; Tara Glynos; Alexis Thompson; Patricia Giardina; Paul Harmatz; Barinder P Kang; Carole Paley; Thomas D Coates
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

9.  Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.

Authors:  Rui Cui; Robert Peter Gale; Guoqing Zhu; Zefeng Xu; Tiejun Qin; Yue Zhang; Gang Huang; Bing Li; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal:  Leuk Res       Date:  2014-02-10       Impact factor: 3.156

Review 10.  Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

Authors:  Adam E Gaweda; Yelena Z Ginzburg; Yossi Chait; Michael J Germain; George R Aronoff; Eliezer Rachmilewitz
Journal:  Nephrol Dial Transplant       Date:  2014-05-12       Impact factor: 5.992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.